Solution structure of mu-conotoxin PIIIA, a preferential inhibitor of persistent tetrodotoxin-sensitive sodium channels by Nielsen, Katherine J. et al.
Solution Structure of -Conotoxin PIIIA, a Preferential Inhibitor of
Persistent Tetrodotoxin-sensitive Sodium Channels*
Received for publication, February 17, 2002, and in revised form, April 29, 2002
Published, JBC Papers in Press, May 2, 2002, DOI 10.1074/jbc.M201611200
Katherine J. Nielsen‡, Michael Watson§, David J. Adams§, Anna K. Hammarstro¨m¶,
Peter W. Gage¶, Justine M. Hill‡, David J. Craik‡, Linda Thomas‡, Denise Adams‡,
Paul F. Alewood‡, and Richard J. Lewis‡§**
From the ‡Institute for Molecular Bioscience, University of Queensland, Brisbane 4072, Australia,
the §School of Biomedical Sciences, University of Queensland, Brisbane 4072, Australia,
and the ¶Division of Biochemistry and Molecular Biology, John Curtin School of Medical Research,
Australian National University, Canberra, Australian Capital Territory 2601, Australia
-Conotoxins are peptide inhibitors of voltage-sensi-
tive sodium channels (VSSCs). Synthetic forms of
-conotoxins PIIIA and PIIIA-(2–22) were found to in-
hibit tetrodotoxin (TTX)-sensitive VSSC current but had
little effect on TTX-resistant VSSC current in sensory
ganglion neurons. In rat brain neurons, these peptides
preferentially inhibited the persistent over the tran-
sient VSSC current. Radioligand binding assays re-
vealed that PIIIA, PIIIA-(2–22), and -conotoxin GIIIB
discriminated among TTX-sensitive VSSCs in rat brain,
that these and GIIIC discriminated among the corre-
sponding VSSCs in human brain, and GIIIA had low
affinity for neuronal VSSCs. 1H NMR studies found that
PIIIA adopts two conformations in solution due to cis/
trans isomerization at hydroxyproline 8. The major
trans conformation results in a three-dimensional struc-
ture that is significantly different from the previously
identified conformation of -conotoxins GIIIA and
GIIIB that selectively target TTX-sensitive muscle
VSSCs. Comparison of the structures and activity of PIIIA
to muscle-selective -conotoxins provides an insight into
the structural requirements for inhibition of different
TTX-sensitive sodium channels by -conotoxins.
Voltage-sensitive sodium channels (VSSCs)1 underlie the in-
flux of sodium ions responsible for action potentials in excitable
cells (1). Based on their susceptibility to block by tetrodotoxin
(TTX), VSSCs can be divided into TTX-sensitive (TTX-S) and
TTX-resistant (TTX-R) classes. Members of both classes share
considerable sequence homology and are closely related struc-
turally (2). These include the neuronal TTX-S type I/Nav1.1,
type II/Nav1.2, type III/Nav1.3, PN1/Nav1.7 and PN4/Nav1.6,
and the skeletal muscle TTX-S 1/Nav1.4. The TTX-R sodium
channels include the cardiac H1/Nav1.5, which is partially
TTX-resistant, and the neuronal TTX-R channels SNS/PN3/
Nav1.8 and NaN/PN5/Nav1.9 (2). A number of these VSSC
subtypes are implicated in clinical states such as pain (3–6),
stroke (7, 8), and epilepsy (9, 10). Persistent (noninactivating)
forms of the TTX-S sodium channel current that underlie re-
petitive firing (11, 12) have less well defined origins but may
involve Nav1.3 (13) or Nav1.6 (11) and are enhanced by hypoxia
(14–16) and nitric oxide (17). Most TTX-S sodium channels
types have a heterogeneous distribution in human brain (18).
VSSCs are inhibited by local anesthetics and modulated by
toxins that act at one inhibitory site (site 1) and at least four
other sites that result in excitatory actions. -Conotoxins from
the venom of marine cone snails act selectively to occlude the
pore of the VSSC by competing with TTX and saxitoxin (STX)
for binding to site 1 in the P-loop region of the  subunit. To
date, sequences for four members of the three-loop -conotoxin
class have been published (Table I). GIIIAGIIIC from Conus
geographus venom are potent blockers of skeletal muscle but
not neuronal VSSCs. The three-dimensional structures of se-
lected -conotoxins (19, 20) have been used to describe the
architecture of the outer vestibule of the VSSC (21–25). The
most recently described member of this class is -conotoxin
PIIIA (26) from C. purpurescens (Fig. 1). PIIIA is notable for its
ability to inhibit neuronal as well as muscle TTX-S sodium
channels (26) and to discriminate among VSSCs in rat brain
(27). Thus, PIIIA is the first peptide toxin for investigating the
architecture of site 1 of neuronal VSSCs.
Previous studies on GIIIA (21, 22) have revealed that the
cationic residues, particularly Arg13, are important for the high
potency of this peptide at Nav1.4 (see Fig. 1). The high sequence
identity and similarities in the three-dimensional structures of
GIIIA and GIIIB (19, 20) provide a rational basis for compari-
son with PIIIA, which also contains a number of conserved
residues and the same disulfide connectivities as GIIIA and
GIIIB (and GIIIC). However, a number of primary structural
differences are apparent between PIIIA and other -conotox-
ins, which may affect the relative position and orientation of
backbone loops and their projecting side chains and thus allow
PIIIA to interact with both neuronal and muscle forms of
TTX-sensitive VSSCs.
To further investigate the potential of PIIIA as a probe of
VSSCs, we determined its structure by 1H NMR spectroscopy
and characterized its mode of action on native tissues using
electrophysiological and ligand binding approaches. These
studies revealed that PIIIA and PIIIA-(2–22) preferentially
inhibited the persistent TTX-S currents in rat hippocampal
neurons, whereas in rat DRG the TTX-R current was spared.
Comparisons of the three-dimensional structures of PIIIA,
GIIIA, and GIIIB revealed important structural differences,
* This work was supported by a GIRD grant from AusIndustry with
AMRAD Operations Ltd., by an Australian Research Council Special
Research Centre for Functional and Applied Genomics, and by the
National Health and Medical Research Council, Australia.
 An ARC Professorial Fellow.
** To whom correspondence should be addressed: Institute for Mo-
lecular Bioscience, University of Queensland, Brisbane, Queensland
4072, Australia. Tel.: 61-7-3365-1925; Fax: 61-7-3365-1990.
1 The abbreviations used are: VSSC, voltage-sensitive sodium chan-
nel; TTX, tetrodotoxin; TTX-S, TTX-sensitive; TTX-R, TTX-resistant;
TES, 2-{[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]amino}ethanesulfonic
acid; STX, saxitoxin; NOE, nuclear Overhauser effect; NOESY, NOE
spectroscopy; Hyp, hydroxyproline; r.m.s., root mean square.
THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 277, No. 30, Issue of July 26, pp. 27247–27255, 2002
© 2002 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in U.S.A.
This paper is available on line at http://www.jbc.org 27247
 by on Septem
ber 7, 2006 
w
w
w
.jbc.org
D
ow
nloaded from
 
including an alternative major conformation accessed by PIIIA,
which had not been identified previously in -conotoxins.
EXPERIMENTAL PROCEDURES
Peptide Synthesis
Peptides were prepared by Boc chemistry (28) using methods de-
scribed for -conotoxins (29). The side chain protection chosen was
Arg(tos), Asp(OcHex), Lys(CIZ), Ser(Bzl), and Cys(p-MeBzl). The crude
reduced peptides were purified by preparative chromatography, using a
1% gradient (100% A to 80% B, 80 min) and UV detection at 230 nm.
The reduced peptides were oxidized at a concentration of 0.02 mM in
either aqueous 0.33 M NH4OAc, 0.5 M guanidine HCl or aqueous 2 M
NH4OH. The solution was stirred for 3–5 days at pH 8.1. Purification of
oxidized peptide was completed using preparative reversed phase high
pressure liquid chromatography.
Radioligand Binding
Whole rat brain (29), the human frontal cortex (30), and rat skeletal
muscle (31) were homogenized in 50 mM HEPES (pH 7.4), filtered
though 100-m nylon mesh (muscle only), and centrifuged at 28,000 
g (10 min). The pellet was suspended in 50 mM HEPES, 10 mM EDTA
(pH 7.4) for 30 min, centrifuged, and resuspended in 50 mM HEPES (pH
7.4). Radioligand binding studies were conducted in assay buffer (130
mM choline chloride, 5.4 mM KCl, 5.5 mM glucose, 0.8 mM MgSO4, 1.8
mM CaCl2, 50 mM HEPES (pH 7.4 with Tris base)). Assays were con-
ducted on rat brain (18 g of protein, 150-l total volume), human brain
(12 g of protein, 150 l), and rat muscle (50 g of protein, 300 l) that
contained 5.6 nM [3H]STX (14.9 Ci/mmol; Amersham Biosciences) and
varying concentrations of -conotoxins in assay buffer. Assays were
incubated for 1 h at 4 °C and filtered through GFB filters on a Tomtec
harvester (brain) or a Millipore manifold (muscle) using wash buffer
(163 mM choline chloride, 1.8 mM CaCl2, 0.8 mM MgSO4, 5.0 mM HEPES
(pH 7.4 with Tris base)). Filters were dried, scintillant was added, and
filters retained radioactivity measured on a Microbeta counter (Wallac).
Electrophysiological Experiments
Electrophysiological experiments were conducted to further investi-
gate the effect of PIIIA on TTX-S and TTX-R sodium channels in native
tissue.
Dissociation of Nodose and DRG Neurons—Sensory neurons from rat
nodose ganglia and dorsal root ganglia (DRG) were isolated as previ-
ously described (32, 33). Briefly, young rats (1021 days) were killed by
cervical dislocation, and the nodose and DRG were carefully removed.
The ganglia were placed in physiological saline solution containing
collagenase (1.0 mg/ml type 2; Worthington-Biochemical) and incu-
bated for 1 h at 37 °C in 95% air and 5% CO2 for 24–48 h. Neurons from
the nodose ganglia that were clear and round were selected for exper-
iments. Small diameter cells (20 m) from the DRG were used, since
these have previously been reported to predominantly express TTX-
resistant Na currents (34).
Dissociation of Hippocampal CA1 Neurons—Young rats (1421
days) were anesthetized under CO2 and decapitated with an animal
guillotine. The brain was removed and transferred to ice-cold artificial
cerebrospinal fluid (containing 124 mM NaCl, 26 mM NaH2CO3, 3 mM
KCl, 1.3 mM MgSO4, 2.5 mM NaH2PO4, and 20 mM glucose). The brain
was mounted in a vibratome and bathed in ice-cold artificial cerebro-
spinal fluid equilibrated with 95% O2 and 5% CO2 while the 500-m-
thick slices were prepared. Brain slices were incubated for 30 min with
200 units/ml papain (Worthington), 1.1 mM cysteine (Sigma), 0.2 mM
EDTA, and 13.4 mM mercaptoethanol at 35 °C. Following incubation,
the CA1 region was located, removed, and gently triturated using a
fire-polished Pasteur pipette. Neurons of 10–15 m were used, and cells
that were flat, swollen, or grainy in appearance were avoided.
Electrophysiological Recordings—Whole cell Na currents were re-
corded using the patch clamp technique. Patch pipettes (GC150F; Har-
vard Apparatus Ltd., Edenbridge, Kent, UK) were prepared that had
resistances of between 1 and 2 megaohms (nodose and DRG neurons)
and between 6 and 10 megaohms (CA1 neurons) when filled with
pipette solution. Whole cell Na currents from nodose and DRG neu-
rons were made using a List EPC 7 amplifier (List Medical). Voltage
steps were generated by a PC (Dell Pentium) running pClamp (Axon
Instruments Inc., Union City, CA). Whole cell Na currents from CA1
neurons were made using a Axopatch 1D amplifier (Axon Instruments)
with voltage steps generated using a PC (Osborne 486-SX) running
custom software (14, 15, 35).
Solution and Toxins—To record Na currents from DRG and nodose
neurons, patch pipettes were filled with the following solution: 135 mM
CsF, 10 mM NaCl, 5 mM HEPES, with pH adjusted to 7.2 with CsOH.
The bath solution contained 50 mM NaCl, 3 mM KCl, 90 mM tetraeth-
ylammonium chloride, 0.1 mM CdCl2, 7.7 mM glucose, 10 mM HEPES,
with pH adjusted to 7.4 with TEA-OH. To record Na currents from
CA1 neurons, the patch pipette solution contained the following solu-
tion: 125 mM CsF, 5 mM NaF, 10 mM KCl, 10 mM TES, with pH adjusted
to 7.4 with KOH. The bath solution contained 135 mM NaCl, 5 mM KCl,
3 mM MgCl2, 1 mM CaCl2, 5 mM CoCl2, 5 mM CsCl, 10 mM TES, with pH
adjusted to 7.4 with NaOH.
Data Analysis—Three distinct Na currents were measured: a tran-
sient TTX sensitive Na current (TTX-S INaT), a transient TTX-resist-
ant Na current (TTX-R INaT), and a persistent TTX-sensitive Na

current (TTX-S INaP). The amplitude of evoked TTX-S INaT was meas-
ured at its peak after subtraction of the current evoked in the presence
of TTX (0.51 M). The amplitude of the TTX-R INaT was measured at
least 2 min following the addition of 0.51 M TTX. The amplitude of
TTX-S INaP was measured at the end of a 400-ms voltage step after
subtraction of the current evoked in the presence of TTX (0.51 M). All
values are expressed as means  S.E. with n indicating the number of
cells in a given series of experiments. Comparisons of two means were
made using Student’s two-tailed unpaired t test.
1H NMR Spectroscopy
All NMR experiments were recorded on a Bruker ARX 500 spectrom-
eter equipped with a z-gradient unit or on a Bruker DMX 750 spectrom-
eter equipped with an x,y,z-gradient unit. Peptide concentrations were
2 mM. PIIIA was examined in 95% H2O, 5% D2O (pH 3.0 and 5.5;
275–298 K) and in 50% aqueous CD3CN (260–293 K).
1H NMR exper-
iments recorded were NOESY (36, 37) with mixing times of 150, 200,
and 400 ms, TOCSY (38) with a mixing time of 80 ms, DQF-COSY (39),
and E-COSY in 100% D2O (40). All spectra were run over 6024 Hz (500
MHz) or 8192 Hz (750 MHz) with 4 K data points, 400–512 free
induction decays, 16–64 scans, and a recycle delay of 1 s. The solvent
was suppressed using the WATERGATE sequence (41). Spectra were
processed using UXNMR as described previously (29) and using Aure-
lia; subtraction of background was used to minimize T1 noise. Chemical
shift values were referenced internally to 4,4-dimethyl-4-silapentane-
1-sulfonate at 0.00 ppm. Secondary H shifts were measured using
random coil shift values of Wishart et al. (42). 3JNH-H coupling con-
stants were measured as previously described (29).
Distance Restraints and Structure Calculations
Peak volumes in NOESY spectra were classified as strong, medium,
weak, and very weak, corresponding to upper bounds on interproton
distance of 2.7, 3.5, 5.0, and 6.0 Å, respectively. Lower distance bounds
were set to 1.8 Å. Appropriate pseudoatom corrections were made (43),
and distances of 0.5 and 2.0 Å were added to the upper limits of
restraints involving methyl and phenyl protons, respectively. 3JNH-H
coupling constants were used to determine  dihedral angle restraints
(44), and in cases where 3JNH-H was 68 Hz and it was clear that a
positive dihedral angle was not present,  was restrained to 100 
70°. 3JH-H coupling constants, together with relevant NOESY peak
strengths, were used to determine x1 dihedral angle restraints (45).
Where there was no diastereospecific assignment for a prochiral pair of
protons, the largest upper bound for the two restraints was used. Where
stereospecific assignments were established, these distances were spec-
ified explicitly.
Structures were calculated using the torsion angle dynamics/simu-
lated annealing protocol in X-PLOR (46) version 3.8 using a modified
geometric force field based on parhdg.pro. Structure refinements were
performed using energy minimization (200 steps) under the influence of
a full force field derived from Charmm (47) parameters. Structure
modeling, visualization, and superimpositions were done using In-
FIG. 1. Primary sequence of -conotoxins GIIIA, GIIIB, GIIIC
(60), and PIIIA (26) with disulfide connectivity indicated. Stand-
ard one-letter codes are used for amino acids, except for pyroglutamic
acid (pE) and hydroxyproline (O). Common residues found important
for binding in GIIIA (21) are boxed. PIIIA-(2–22) is a truncated deriv-
ative of PIIIA in which the terminal pyroglutamate is absent. Lines
indicate cysteine connectivity.
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sightII (MSI). Surface calculations, r.m.s. deviations, and hydrogen
bond analysis were done using MOLMOL (48). The quality of the
structures was analyzed using procheck-NMR (49).
RESULTS
Effects of PIIIA and PIIIA-(2–22) on Neuronal Whole Cell
Na Currents—The effects of -conotoxin PIIIA and a trun-
cated analogue, PIIIA-(2–22), were investigated on three dis-
tinct VSSCs found in neurons of the peripheral and central
nervous system. Rat nodose ganglion neurons were used to
investigate the transient TTX-sensitive voltage-dependent
Na current (TTX-S INaT), DRG neurons were used to investi-
gate the transient TTX-resistant sodium current (TTX-R INaT)
(34), and rat hippocampal neurons in the CA1 region were used
to investigate the persistent TTX-sensitive sodium current
(TTX-S INaP) (15, 50, 51).
PIIIA-(2–22) caused a concentration-dependent reduction in
the peak amplitude of the TTX-S INaT in rat nodose ganglia
neurons (Fig. 2). In contrast, in rat DRG neurons (n  12),
PIIIA-(2–22) produced only a small reduction in the peak am-
plitude of the TTX-R INaT (Fig. 2). High frequency stimulation
can modify the degree of block by some neurotoxins that act in
a use-dependent manner. Compared with control, 1 M PIIIA-
(2–22) failed to produce any use-dependent inhibition of peak
TTX-S INaT during 20 depolarizing pulses from a holding po-
tential of 80 mV to a test potential of 30 mV for 25 ms
delivered at a frequency of 20 Hz (n  6). In rat hippocampal
CA1 neurons, the addition of PIIIA-(2–22) to the bathing solu-
tion caused a concentration-dependent reduction in the peak
amplitude of the TTX-S INaT and the TTX-S INaP (Fig. 3).
Interestingly, PIIIA-(2–22) had a greater effect on the TTX-S
INaP than on the TTX-S INaT (Fig. 3, inset). At 1 M, the peak
amplitude of the TTX-S INaT was unaffected, whereas the am-
plitude of the TTX-S INaP was reduced by 70%.
The native -conotoxin, PIIIA, also reduced the TTX-S INaT
in rat nodose (n  12), DRG (n  3), and CA1 (n  3) neurons
(data not shown) with a similar potency to PIIIA-(2–22). PIIIA
had a preferential effect on the persistent compared with the
transient sodium current, being slightly more potent at reduc-
ing the amplitude of the TTX-S INaT current in CA1 neurons
than PIIIA-(2–22). In preliminary experiments, 10-min bath
application of GIIIB (1–10 M) had no effect on either the
TTX-S or TTX-R INaT in rat nodose or DRG neurons, respec-
tively (n  3; data not shown).
Radioligand Binding Studies—–The ability of -conotoxins
to displace [3H]STX from VSSCs in human and rat brain and
rat skeletal muscle is shown in Fig. 4. All peptides were more
potent at the rat skeletal muscle than rat brain VSSCs, with
GIIIA and GIIIC showing most selectivity and PIIIA least
selectivity. The pIC50 values and percentage inhibition for
these peptides are given in Table I. The data show that PIIIA
and PIIIA-(2–22) have greatest potency at rat and human brain
VSSCs, GIIIB has intermediate potency, and GIIIA and GIIIC
have least potency. These peptides were less potent than TTX,
with none able to fully displace [3H]STX from rat or human
brain (relative to TTX displacement). PIIIA and PIIIA-(2–22)
produced the largest displacement of [3H]STX, and GIIIA and
GIIIC produced the least displacement. GIIIB was more effec-
tive at displacing [3H]STX from rat compared with human
brain (Fig. 4, A and B). All displacement curves were best fitted
with a Hill slope of 1.
1H NMR Spectroscopy—–PIIIA was examined by 1H NMR
spectroscopy in a range of different solvent conditions. In aque-
ous solution at pH 2.55.5 over 275298 K, it was apparent
that two conformations of PIIIA were present in a3:1 ratio. In
aqueous solution at low pH over 283298 K, the NH reso-
nances of several residues, including 47, 1012, 20, and 22,
FIG. 2. Effects of PIIIA-(2–22) on transient TTX-sensitive and
TTX-resistant Na currents recorded in nodose and DRG neu-
rons. Shown are Na currents recorded from a nodose ganglia neuron
(A) and a DRG neuron (B) in control solution and in the presence of
0.1–10 M PIIIA-(2–22). The records shown in B were obtained in the
continued presence of 1 M TTX to measure effects on the TTX-R
current. C, dose-response relationship showing the effects of PIIIA-(2–
22) on the transient TTX-resistant Na current recorded from DRG
neurons () and the effects of PIIIA on the transient TTX-sensitive Na
current recorded from nodose neurons (E). Each point represents the
mean current amplitude from at least three cells obtained following a
voltage step to 30 mV from a holding potential of 80 mV.
FIG. 3. Effects of PIIIA-(2–22) on the transient and persistent
TTX-sensitive Na currents recorded from hippocampal CA1
neurons. Na currents recorded from a hippocampal CA1 neuron
showing the effects of PIIIA-(2–22) on the transient TTX-sensitive Na
current and the persistent Na current. Inset, the differential effects of
PIIIA-(2–22) on the amplitude of the transient and persistent Na
current. Peak amplitudes of the transient and persistent current were
normalized to the transient and persistent currents recorded in control
solution. Each point represents the mean current amplitude from at
least three cells obtained following a voltage step to 30 mV from a
holding potential of 80 mV (prepulsed to 130 mV for 300 ms).
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were broad, and that of Cys21 was not observable. At higher pH
values and lower temperatures (275 K), these peaks sharpened
(residues 4 and 5) or separated into two distinct sets of peaks
(residues 6 and 7, 1012, 20, and 22) so that complete assign-
ment of the major and a partial assignment of the minor con-
formations was possible. The assignment of PIIIA was im-
proved by the addition of up to 50% CD3CN, where the set of
peaks arising from the minor conformation was less evident,
and all resonances from the major conformation were present.
Chemical shift assignments for PIIIA are given in Table II.
The two hydroxyproline (Hyp) residues in PIIIA are assigned
as trans from the observation of strong H-Hi  1 NOEs in the
case of Hyp8 and weak to medium H-Hi  1, together with the
stronger H-Hi  1 NOEs in the case of Hyp
18 (52). The minor
conformation of PIIIA results from a cis conformation of Hyp8,
indicated by a H-Hi  1 NOE to the preceding residue. PIIIA-
(2–22) was also examined under similar conditions and found
to have almost identical chemical shifts and to adopt two con-
formations in proportions similar to those observed for PIIIA.
The remainder of this paper describes the major conformation
observed for both PIIIA and PIIIA-(2–22), unless otherwise
specified.
Secondary H shifts were used to examine the effects of
solvent conditions on the backbone structure of PIIIA (Fig. 5).
The shifts of PIIIA-(2–22) are also shown. These results clearly
indicate that the backbone conformation is the same over a
range of pH and solvent conditions for the native and truncated
sequences. Similarly, the differences in H shifts for AMX-
bearing side chains, the H shifts of the two Hyp residues, and
the H shifts of Gly6 remain largely unchanged over these
conditions for PIIIA and PIIIA-(2–22) (data not shown), indi-
cating that the conformations of the side chains are not signif-
icantly affected by changes in the solution environment. One
exception is the H protons of Cys4, where the chemical shift
differences between the H2/H3 protons increase with pH
from 0.22 ppm at pH 3 to 0.66 ppm at pH 5. This is likely to
arise from the ring current effect of an aromatic ring in prox-
imity to the side chain of Cys4 at higher pH.
Comparison of the H shifts of the minor conformation of
PIIIA show significant differences from residues 711, indicat-
ing differences in backbone conformation in these regions. This
is supported by differences in H shifts that are evident from
residues 611, and also at Cys16. Due to low signal intensities,
it was not possible to observe peaks for both H and protons of
Cys4, Cys5, and Cys21. The ring current effects observed for H
protons of the major conformations of PIIIA were not present in
the minor conformations, indicating a difference in the posi-
tions of either Phe7 or His19 relative to Cys4.
Fig. 5 also compares the secondary H shifts of PIIIA with
those of GIIIB, which adopts the same structure in solution as
GIIIA (20). Overall, the trends are similar, indicating that the
global fold of PIIIA and GIIIB are similar, as may be expected
based on their identical disulfide pairings and loop sizes (Fig.
1). However, differences observed at residues 511 and 1920
indicate that in some regions significant structural divergence
exists. To directly address potential structural differences, we
determined the three-dimensional structure of the major con-
formation PIIIA (see below). Interestingly, the secondary shifts
of the minor conformation of PIIIA at residue 10 are more like
those of GIIIB than the major form of PIIIA (Fig. 5), suggesting
that the structure of the minor conformation of PIIIA is similar
to the major conformation of GIIIB and GIIIA.
The local medium range NMR data that provide information
on the secondary structure of PIIIA are given in Fig. 6. The
presence of several H-NHi  2, NH-NHi  2, and H-NHi  3
NOEs are indicative of the presence of several turns over the
entire peptide and perhaps helix over residues 1317. Al-
though several long range NOEs are present, these did not
correspond to the long range NOEs prescribing the -hairpin of
GIIIB (20). In fact, a number of long range NOEs were present
that preclude a corresponding -hairpin in the major confor-
mation of PIIIA.
At higher pH values (4.0 at 293 K) in aqueous solution or in
50% aqueous CD3CN, the hydroxyl proton of Ser
13 side chain
was observed. This resonance sharpened considerably with the
lowering of temperature (275 K in H2O; 260 K in CD3CN) to
reveal several medium range NOEs to residues 15 and 16,
indicative of a hydrogen bond involving the side chain of Ser13.
These flanking residues apparently stabilize the position of
Arg14, which has been shown to be crucial to the potency of
FIG. 4. Displacement of [3H]STX from brain and skeletal mus-
cle VSSC by TTX and -conotoxins PIIIA, PIIIA-(2–22), GIIIA,
GIIIB, and GIIIC. A, human brain; B, rat brain; C, rat skeletal muscle;
D, neuronal versus skeletal muscle selectivity in rat tissue. Legend
refers to A, B, and C.
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PIIIA (26). No equivalent interaction has been observed previ-
ously for either GIIIA or GIIIB, although an Asp in the equiv-
alent position could conceivably stabilize the crucial Arg13
through the formation of a hydrogen bond with Gln14 (GIIIA) or
through a salt bridge with Arg14 (GIIIB).
Three-dimensional Structure of PIIIA—A total of 372 NOE-
derived distance restrained (149 intraresidual, 98 sequential,
125 long/medium range) and 27 dihedral (16  and 11 1) were
used to generate a set of 50 structures of PIIIA. Of these, 46
converged to a similar fold with no NOE violations greater than
0.2 Å and no dihedral violations greater than 3°. The structural
analysis and data indicating the quality of the structures are
summarized in Table III. From this, it is apparent that the
backbone structure is highly defined over residues 322, a
conclusion that is supported by high average angular order
parameters (S 0.96) over this region for the  and  backbone
dihedral angles and low backbone r.m.s. deviations (Fig. 7A).
Fig. 8A shows an overlay of the 20 lowest energy structures,
which indicate that PIIIA is dominated by a series of turns over
the N-terminal part of the molecule. From Ser13 to the C
terminus, the structure adopts a distorted helix, with devia-
tions from ideality at residues 18 and 19. Fig. 8B shows the
positions of the side chains of residues 1315, where it is clear
that the exposure of Arg14 is facilitated by the proximity of
Ser13 and Gln15. Analysis of the structures indicate the pres-
ence of hydrogen bonds between the side chain oxygen of Ser13
and the backbone NH proton of Cys15 (16 of 20 structures) or
Gln15 (11 of 20 structures) or the side chain amide protons of
Gln15 (1 of 20 structures), which would assist in stabilizing this
configuration.
Examination of the structures of PIIIA reveals that the po-
sitions of some side chains are less precisely defined than
others. Although there has been no quantitative investigation
of the correlation between surface exposure and geometric pre-
cision within families of NMR-derived structures, it might be
expected that more surface-exposed residues are less confor-
mationally constrained than buried residues. To investigate
this correlation for PIIIA, the surface area of each residue is
compared with the heavy atom r.m.s. deviations for each resi-
due in Fig. 7B. From this plot, it is evident that surface expo-
sure correlates with r.m.s. deviation values (r2  0.83 for all
residues, r2  0.90 for residues 322). This comparison pro-
TABLE I
Potency (pIC50) and extent of inhibition (%) of [
3H]STX binding to VSSCs by -conotoxins and TTX
95% confidence interval range for pIC50 and percentage of inhibition are given in parenthesis.
-Conotoxin Human brain Rat brain Rat muscle
PIIIA
Potency 7.1 (7.6–6.6) 6.5 (6.8–6.3) 6.8 (7.1–6.5)
Inhibition 47 (34–61)% 79 (68–91)% 81 (67–96)%
PIIIA-(2–22)
Potency 6.6 (7.0–6.2) 6.4 (6.6–6.3) 7.2 (7.4–7.0)
Inhibition 70 (58–82)% 90 (86–94)% 81 (73–93)%
GIIIA
Potency Inactive 5.1 (5.5–4.7) 7.1 (7.3–6.9)
Inhibition 40 (28–52)% 82 (76–89)%
GIIIB
Potency 5.5 (6.4–4.5) 5.9 (6.2–5.7) 7.2 (7.5–7.0)
Inhibition 36 (17–54)% 87 (72–101)% 85 (78–92)%
GIIIC
Potency 6.0 (6.6–5.4) Inactive 7.3 (7.5–7.1)
Inhibition 30 (20–41)% 93 (86–101)%
TTX
Potency 7.6 (7.8–7.4) 7.8 (7.9–7.7) 7.8 (7.9–7.7)
Inhibition 98 (91–105)% 100 (97–103)% 100 (96–104)%
TABLE II
1H chemical shifts of PIIIA
Values not in parenthesis or brackets are for the major conformation in acetonitrile/H2O (1:1) at pH 3.0 and 280 K; values in parentheses (major
conformation) and brackets [minor conformation] were measured in H2O at pH 5.0 and 285 K.
Residue NH H H Other
pGlu1 (7.98) (4.29)[4.33]
Arg2 (8.53)[8.59] 3.93 (4.25)[4.19] 1.79 H	 1.52; H 2.92, 2.97; NH 7.07
Leu3 8.47 (8.45)[8.48] 4.40 (4.41)[4.32] 1.57 H 0.88
Cys4 8.41 (8.43)[8.43] 4.47 (4.58) 2.34, 2.56
Cys5 7.97 (8.03) 4.14 (4.28) 3.00, 3.47
Gly6 8.38 (8.65)[7.84] 3.83 (3.81, 3.82)
[3.63, 4.11]
Phe7 7.38 (7.43)[8.35] 4.98 (5.05)[4.72] 2.98, 3.13 H, H
 7.19; H 7.23
Hyp8 4.41 (4.49)[4.28] 2.05, 2.34 H	 4.67; H 3.75, 3.90
Lys9 8.55 (9.02)[8.87] 3.98 (4.07)[4.11] 1.93 H	 1.34; H 1.6; H
 2.90; 
NH3 7.49
Ser10 7.78 (7.92)[8.63] 3.98 (4.05)[4.79] 3.82, 3.37
Cys11 8.08 (8.25)[8.34] 4.39 (4.51)[4.62] 3.12, 2.91
Arg12 7.50 (7.52)[8.43] 4.19 (4.28)[4.31] 1.84, 1.98 H	 1.66, 1.72; NH 7.26
Ser13 7.73 (7.86)[7.90] 4.48 (4.53)[4.43] 3.99, 4.18 (OH 5.72)
Arg14 9.04 (9.19)[9.16] 3.95 (4.01)[3.99] 1.88 H	1.67; H 3.18; NH 7.27
Gln15 8.51 (8.77)[8.72] 4.10 (4.15)[4.16] 2.01 H	 2.39, 6.84; NH2 7.46
Cys16 7.46 (7.62)[7.62] 4.81 (4.81)[4.88] 3.00, 3.18
Lys17 8.06 (7.99)[8.06] 4.21 (4.20)[4.16] H	 1.65, 1.70; H 1.84
Hyp18 4.58 (4.70) 2.32, 1.79 H	 4.46; H 3.74, 3.24
His19 8.18 (8.17) 4.37 (4.25)[4.24] 3.31, 3.34 H
 7.35
Arg20 8.93 (9.22)[8.96] 4.03 (4.12)[4.11] 1.89 H	 1.70; H 3.17; NH 7.24
Cys21 8.49 4.47 (4.48) 3.11, 3.63
Cys22 7.87 (8.13) 4.86 (4.91)[4.89] 3.11, 3.29 NH2 7.30
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vides an additional means of checking and comparing NMR-
derived structures, beyond a comparison of r.m.s. deviation
values alone.
DISCUSSION
The present study confirms that -conotoxins PIIIA and
PIIIA-(2–22) are potent blockers of neuronal VSSCs. It has
been previously shown in radioligand binding studies that
PIIIA and GIIIA discriminate among subtypes of the TTX-
sensitive VSSC found in rat brain (26). This discrimination now
extends to PIIIA-(2–22) and GIIIB in rat brain and to all
-conotoxins except GIIIA in human brain. These differences in
potency and extent of inhibition of rat and human brain VSSCs
arise from relatively small sequence differences, with positions
14 and 18 influencing neuronal activity among the muscle-
selective -conotoxins. Despite differential effects on neuronal
TTX-S sodium channels in brain, GIIIA, GIIIB, and GIIIC have
similar potency at skeletal muscle VSSCs. In the peripheral
nervous system, PIIIA-(2–22) and PIIIA inhibit TTX-S VSSCs
without significantly affecting the TTX-R sodium current.
Since -conotoxins have been shown to bind higher in the pore
of Nav1.4 than TTX (53), it would appear that in addition to
residue differences deep within the pore of the VSSC that
render the channel TTX-R (54), additional changes occur fur-
ther out in the pore to render TTX-R VSSCs insensitive to block
by -conotoxins.
PIIIA and its analogue PIIIA-(2–22) are the first -conotox-
ins shown to distinguish between transient and persistent
TTX-sensitive subtypes. Selective inhibition of persistent over
transient VSSCs may control seizures, where the accompany-
ing slow persistent sodium currents might be blocked without
affecting the transient action potentials (7). It has been postu-
lated that the persistent sodium channels are the same as
those that generate transient sodium currents and that a small
fraction of these channels enter a noninactivating mode to
generate the persistent sodium current (55, 56). This type of
persistent current has been observed in cell lines transfected
FIG. 5. Secondary H shifts of PIIIA in aqueous solution at pH 4.5 (A), PIIIA-(2–22) in aqueous solution at pH 4.5 (B), PIIIA in
aqueous solution at pH 3 (C), PIIIA-(2–22) in 50% aqueous CD3CN at pH 3 (D), minor conformation of PIIIA in aqueous solution at
pH 4.5 (E), and GIIIB in aqueous solution at pH 3.5 (20) (F). The PIIIA and PIIIA-(2–22) measurements were made at 285 K. The numbering
is based on PIIIA residues and alignment on the position of cysteine residues (see Fig. 1). The chemical shift for Cys5 in the minor conformation
of PIIIA is omitted, since it was not clearly observed.
FIG. 6. Local and medium range
NOE, 3JNH-Ha coupling constant, and
slow exchange data for PIIIA (pH 3,
280 K, 100% D2O). Open circles, NH pro-
tons that are present 2 h after the addi-
tion of D2O. Open squares,
3JNH-H  6
Hz; filled squares, 3JNH-H  8.5 Hz; par-
tially filled squares, 6 Hz  3JNH-H  8
Hz. For NOE data, the height of bars in-
dicates the strength of NOE. Open bars
indicate peak overlap. Sequential NOEs
involving Hi-Hi  1 and Hi-HNi  1 dis-
tances, where i  Hyp are represented in
the dN(i, i  1) and dNN(i, i  1) sec-
tions, respectively.
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with cDNA for Nav1.6 (11), Nav1.3 (13), or Nav1.2 (57). The
persistent Na current is also thought to play an important
role in pacemaking currents and setting rythmicity in central
neurons (58). During hypoxia or in the presence of free radicals
(oxidative stress), these channels become more active (15, 17,
35) and could thus serve as a prominent pathway for Na
influx, triggering a cascade of damaging events that eventually
cause cell damage and cell death (59). Hence, specific inhibitors
of persistent Na current may have neuroprotective effects.
TTX, lidocaine, and quinidine can also inhibit persistent Na
channels without blocking transient Na channels (14, 15).
The -conotoxins extend the list of blockers able to discrimi-
nate between persistent and transient sodium currents.
Insights into the structure of the outer vestibule of the
Nav1.4 channel have been obtained using the three-dimen-
sional structure GIIIA and GIIIB as molecular calipers (21–23).
The fact that PIIIA is also able to block Nav1.4 indicates that
many of the structural features found in GIIIA and GIIIB
might also be conserved in PIIIA. However, additional struc-
tural differences must also exist to account for the high affinity
of PIIIA and the structurally equivalent PIIIA-(2–22) at both
neuronal and muscle forms of TTX-sensitive VSSCs. The three-
dimensional structures of PIIIA are compared with those of
GIIIA in Fig. 8, C–F. Although the positions of the C-terminal
regions overlap and the positions of the functionally important
Arg14 (Arg13 in GIIIA and GIIIB) are exposed in a similar
manner, further comparison indicates marked differences in
the orientation of the N-terminal region to the end of loop 1 at
Cys 11. In GIIIB, this loop was described as forming a distorted
-hairpin that was suggested to exist also in GIIIA (20). This
structural feature is not present in the major conformation of
FIG. 7. A, backbone angular order parameters for the  and 
didedral angles and average backbone r.m.s. deviations versus PIIIA
residue number. B, heavy atom r.m.s. deviations and the percentage of
surface exposure (Å2) versus PIIIA residue number.
TABLE III
Geometric and energetic statistics for the 20 structures of
-conotoxin PIIIA
Parameter Value
Mean r.m.s. deviations from
experimental restraints
NOE (Å) 0.009  0.002
Dihedral (degrees) 0.21  0.10
Mean r.m.s. deviation from idealized
covalent geometry
Bonds (Å) 0.0079  0.0004
Angles (degrees) 2.14  0.06
Impropers (degrees) 0.19  0.02
Energies (kcal mol1)
ENOE 0.92  0.37
Eedih 0.05  0.04
ELJ 92.9  3.4
Ebond  Eangle  Eimproper 47.3  3.1
Restraint violations
Mean NOE violation (Å) 0.029
Maximum NOE violation (Å) 0.17
Mean dihedral angle violation (degrees) 0.94
Maximum angle violation (degrees) 2.45
FIG. 8. Structure of PIIIA. A, superimposition of the 20 lowest
energy structures over the backbone region (residues 2–22). B, 180y°
rotation of the structures shown in A with the side chains of
Ser13 (pink), Arg14 (blue), Gln15 (purple), and Cys residues (orange)
indicated. A comparison is shown of the positions of surface residues in
PIIIA (C) and their counterparts in GIIIA (D). Note that the same
surface-exposed residues are found in PIIIA and GIIIA and are all
considered important for the potency of GIIIA to 1 VSSCs (Nav1.4). E
and F, comparison of core residues in PIIIA and GIIIA, respectively.
Core residues differ between these two peptides and thus may contrib-
ute to selectivity differences at muscle and neuronal sodium channels.
Side chains shown are Leu/Thr (yellow), Hyp/Ser (pink), Arg/Lys (dark
blue), His (light blue), Gln (purple), Phe (brown), and Asp (red).
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PIIIA, where instead a series of loops exist. The structural
difference between the major and minor forms arises from a
difference at Hyp8 (Hyp7 in GIIIA), which adopts a predomi-
nately trans conformation in PIIIA but a cis conformation in
GIIIA and GIIIB (19, 20). Importantly, residues including Lys8/
Lys9 and Arg1/Arg2, which have been shown in GIIIA to be of
moderate importance to binding, are placed in an entirely
different position in the major conformation of PIIIA (Fig. 8, C
and D). However, the effects of the cis/trans isomerization on
the C-terminal region of PIIIA are minimal, with the confor-
mation of the putatively important binding residues Arg14,
Arg20, and Lys17 not being significantly different from their
GIIIA counterparts. The structural difference between the ma-
jor forms of PIIIA, GIIIA, and GIIIB are unexpected, given that
these peptides share the same disulfide connectivity and loop
sizes and have considerable sequence homology. In contrast,
the minor conformation of PIIIA, like GIIIA and GIIIB, arises
from the cis form of Hyp8/Hyp7, indicating that it adopts a
three-dimensional structure more closely resembling GIIIA
and GIIIB.
Comparison of the major conformation of PIIIA to a model of
the minor conformation of PIIIA derived from the three-dimen-
sional structure of GIIIA (Fig. 9) reveals that the positions of
several side chains differ markedly between the two forms.
Apart from the aforementioned structural differences at Arg2
and Lys9, the hydrophobic residues Leu3 and Phe7 are exposed
to the solvent in the cis form yet hug the surface in the trans
form, providing a different surface profile. In addition, the side
chain of Cys4 lies above the plane of the His19 ring in the trans
conformation (accounting for the ring current effects men-
tioned previously) but lies away from His19 in the cis form,
despite the fact that the position of His19 is unchanged in either
conformation. Thus, a simple cis/trans isomerization not only
affects the surface of this peptide but somewhat surprisingly
also alters the shape of part of the cysteine framework.
Conformational flexibility was proposed as a possible reason
for the broadness of resonances associated with residues in the
loop 2 of GIIIB (20). The present study shows that there are
differing relative proportions and different rates of intercon-
version between the cis/trans forms. In GIIIA and GIIIB, it is
apparent that the cis form predominates, with the trans form
being masked by broadening associated with intermediate ex-
change occurring on the NMR time scale. In PIIIA, the trans
form predominates, but the minor form is detectable because
the two forms are in slow exchange. It is possible that the bulky
Phe residue adjacent to Hyp8 in PIIIA acts to slow the rate of
Hyp isomerization. Two questions arise from the conforma-
tional heterogeneity found in PIIIA. First, which of the possible
-conotoxin conformations binds to the VSSC? Second, what
role is played by these conformational differences in determin-
ing VSSC selectivity among -conotoxins? Given that the
broadened lines observed in GIIIA and GIIIB are indicative of
alternative conformations, it is possible that a minor conforma-
tion of these muscle-selective -conotoxins binds to the VSSCs.
If this is indeed correct, it could impact on studies investigating
the structure of the outer vestibule of the VSSC using the
currently available structures of -conotoxins.
Apart from Arg14, which has been shown to be important for
the activity of PIIIA, it is not known which other residues in
this peptide are involved in VSSC binding. An examination of
the three-dimensional structures and the surface profile (Fig.
7B) of PIIIA reveals residues that are on the surface (Fig. 8C)
and are hence potentially available for interactions with the
sodium channel. Along with Arg14, these include Lys17, Hyp18,
and Arg20, which parallel residues Lys16, Hyp17, and Arg19 in
GIIIA (Fig. 8D), thus defining a common pharmacophore, as
previously suggested (26). Note that Ser13 is buried, consistent
with it playing a structural role that ensures the exposure of
Arg14. In GIIIA, the residue Asp12, which corresponds to Ser13
in PIIIA, may also play a structural role. The other exposed
residues, Lys9 and Arg2, have structural counterparts in GIIIA
(Lys8 and Arg1) but adopt quite different positions in the pre-
dominant conformations of these two peptides.
It is interesting that the residues that differ between PIIIA
and GIIIA cluster on one face of the peptide, perhaps forming a
functionally significant pocket or cavity (Fig. 8, E and F). It is
possible that one or more of these mostly hydrophobic and polar
residues contribute to binding to the neuronal VSSCs and thus
confer broader specificity to PIIIA (and PIIIA-(222)). Thus,
core residues and the positioning of exposed residues that differ
FIG. 9. Comparison of the major conformation of PIIIA (A)
with a modeled structure of its minor conformation (B). The
minor conformation was modeled from the structure of the major con-
formation of GIIIB (20). Structures are superimposed for Arg12 to Cys22.
Side chains are labeled as in Fig. 8.
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between the -conotoxins may contribute to selectivity differ-
ences of -conotoxins at VSSCs. The results from this study
show that the -conotoxin framework is less conformationally
conserved than previously suspected and illustrate the need for
careful analysis of the range of structures this class of conotox-
ins can access. The structure of PIIIA described here provides
a new molecular caliper for neuronal and muscle VSSCs.
REFERENCES
1. Catterall, W. A. (2000) Neuron 26, 13–25
2. Goldin, A. L. Barchi, R. L, Caldwell, J. H., Hofmann, F., Howe, J. R., Hunter,
J. C., Kallen, R. G., Mandel, G., Meisler, M. H., Netter, Y. B., Noda, M.,
Tamkun, M. M., Waxman, S. G., Wood, J. N., and Catterall, W. A. (2000)
Neuron 28, 365–368
3. Akopian, A. N., Souslova, V., England, S., Okuse, K., Ogata, N., Ure, J., Smith,
A., Kerr, B. J., McMahon, S. B., Boyce, S., Hill, R., Stanfa, L. C., Dickenson,
A. H., and Wood, J. N. (1999) Nat. Neurosci. 6, 541–548
4. Eglen, R. M., Hunter, J. C., and Dray, A. (1999) Trends Pharmacol. Sci. 20,
337–342
5. Porreca, F., Lai, J., Bian, D., Wegert, S., Ossipov, M. H., Eglen, R. M.,
Kassotakis, L., Novakovic, S., Rabert, D. K., Sangameswaran, L., and
Hunter, J. C. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 7640–7644
6. Coward, K., Plumpton, C., Facer, P., Birch, R., Carlstedt, T., Tate, S., Bountra,
C., and Anand, P. (2000) Pain 85, 41–50
7. Taylor, C. P., and Meldrum, B. S. (1995) Trends Pharmacol. Sci. 16, 309–316
8. Carter, A. J. (1998) Amino Acids 14, 159–169
9. Ragsdale, D. S., and Avoli, M. (1998) Brain Res. Brain Res. Rev. 26, 16–28
10. Rho, J. M., and Sankar, R. (1999) Epilepsia 40, 1471–1483
11. Smith, M. R., Smith, R. D., Plummer, N. W., Meisler, M. H., and Goldin, A. L.
(1998) J. Neurosci. 18, 6093–6102
12. Bevan, M. D., and Wilson, C. J. (1999) J. Neurosci. 19, 7617–7628
13. Moorman, J. R., Kirsch, G. E., Vandongen, A. M., Joho, R. H., and Brown, A. M.
(1990) Neuron 4, 243–252
14. Ju, Y., Saint, D. A., and Gage, P. W. (1992) Br. J. Pharmacol. 107, 311–316
15. Hammarstro¨m, A. K., and Gage, P. W. (1998) J. Physiol. 510, 735–741
16. Hammarstro¨m, A. K., and Gage, P. W. (2000) J. Physiol. 529, 107–118
17. Hammarstro¨m, A. K., and Gage, P. W. (1999) J. Physiol. 520, 451–461
18. Whitaker, W. R., Faull, R. L. M., Waldvogel, H. J., Plumpton, C. J., Emson,
P. C., and Clare, J. J. (2001) Mol. Brain Res. 88, 37–53
19. Lancelin, J-M., Kohda, D., Tate, S., Yanagawa, Y., Abe, T., Satake, M., and
Inagaki, F. (1991) Biochemistry 30, 6908–6916
20. Hill, J. M., Alewood, P. F., and Craik, D. J. (1996) Biochemistry 35, 8824–8835
21. Chahine, M., Chen, L-Q., Fotouhi, N., Walsky, R., Fry, D., Santarelli, V., Horn,
R., and Kallen, R. G. (1995) Receptors Channels 3, 161–174
22. Chang, N., French, R. J., Lipkind, G. M., Fozzard, H. A., and Dudley, S., Jr.
(1998) Biochemistry 37, 4407–4419
23. Li, R. A., Ennis, I. L., Velez, P., Tomaselli, G. F., and Marban, E. (2000) J. Biol.
Chem. 275, 27551–27558
24. Lipkind, G. M., and Fozzard, H. A. (2000) Biochemistry 39, 8161–8170
25. Li, R. A., Ennis, I. I., French, R. J., Dudley, S. C., Tomaselli, G. F., and Marban,
E. (2001) J. Biol. Chem. 276, 11072–11077
26. Shon, K-J., Olivera, B. M., Watkins, M., Jacobsen, R. B., Gray, W. R., Floresca,
C. Z., Cruz, L. J., Hillyard, D. R., Brink, A., Terlau, H., and Yoshikami, D.
(1998) J. Neurosci. 18, 4473–4481
27. Safo, P., Rosenbaum, T., Shcherbatko, A., Choi, D. Y., Han, E., Toledo-Aral,
J. J., Olivera, B. M., Brehm, P., and Mandel, G. (2000) J. Neurosci. 20,
76–80
28. Schno¨lzer, M., Alewood, P. F., Jones, A., Alewood D., and Kent, S. B. H. (1992)
Int. J. Pept. Protein Res. 40, 180–193
29. Nielsen, K. J., Adams, D., Thomas, L., Bond, T. J., Alewood, P. F., Craik D. J.,
and Lewis, R. J. (1999) J. Mol. Biol. 289, 1405–1421
30. Maddison, J. E., Dodd, P. R., Johnston, G. A. R., and Farrell, G. C. (1987)
Gastroenterology, 93, 1062–1068
31. Yanagawa, Y., Abe, T., Satake, M., Odani, S., Suzuki, J., and Ishikawa, K.
(1988) Biochemistry 27, 6256–6262
32. Jeglitsch, G., Rein, K., Baden, D. G., and Adams, D. J. (1998) J. Pharmacol.
Exp. Ther. 284, 516–525
33. Nicholson, G. M., Walsh, R., Little, M. J., and Tyler, M. I. (1998) Pflugers Arch.
436, 117–126
34. Elliott, A. A., and Elliott, J. R. (1993) J. Physiol. 463, 39–56
35. Ju, Y. K., Saint, D. A., and Gage, P. W. (1996) J. Physiol. (Lond.) 497, 337–347
36. Jeener, J., Meier, B. H., Bachmann, P., and Ernst, R. R. (1979) J. Chem. Phys.
71, 4546–4553
37. Kumar, A., Ernst, R. R., and Wu¨thrich, K. (1980) Biochem. Biophys. Res.
Commun. 95, 1–6
38. Bax, A., and Davis, D. G. (1985) J. Magn. Reson. 65, 355–360
39. Rance, M., Sørenson, O. W., Bodenhausen, G., Wagner, G., Ernst, R. R., and
Wu¨thrich, K. (1983) Biochem. Biophys. Res. Commun. 177, 479–485
40. Greisinger, C., Sorenson, O. W., and Ernst, R. R. (1987) J. Magn. Reson. 75,
474–492
41. Piotto, M., Saudek, V., and Sklena´r, V. (1992) J. Biolmol. NMR 2, 661–665
42. Wishart, D. S., Bigam, C. G., Yao, J., Abildgaard, F., Dyason, H. J., Oldfield,
E., Markley, J. L., and Sykes, B. D. (1995) J. Biomol. NMR 5, 67–81
43. Wu¨thrich, K., Billeter, M., and Braun, W. (1983) J. Mol. Biol. 169, 949–961
44. Pardi, A., Billeter, M., and Wu¨thrich, K. (1984) J. Mol. Biol. 180, 741–751
45. Wagner, G., Braun, W., Havel, T. F., Schaumann, T., Go, N., and Wu¨thrich, K.
(1987) J. Mol. Biol. 196, 611–639
46. Bru¨nger, A. T. (1992) X-PLOR: A System for X-ray Crystallography and NMR,
Version 3.1, Yale University, New Haven, CT
47. Brooks, B., Brucoli, R., Olafson, B. O., States, D., Swaminathan, S., and
Karplus, M. (1983) J. Comput. Chem. 4, 187–217
48. Koradi, R., Billeter M., and Wuthrich, K. (1996) J. Mol. Graph. 51, 29–32
49. Laskowski, R. A., MacArthur, M. W., and Thornton, J. M. (1998) Curr. Opin.
Struct. Biol. 8, 631–639
50. French, C. R., and Gage, P. W. (1985) Neurosci. Lett. 56, 289–293
51. French, C. R., Sah, P., Buckett, K. J., and Gage, P. W. (1990) J. Gen. Physiol.
95, 1139–1157
52. Wu¨thrich, K. (1986) NMR of Proteins and Nucleic Acids, Wiley-Interscience,
New York
53. Dudley, S. C., Jr., Todt, H., Lipkind, G., and Fozzard, H. A. (1995) Biophys. J.
69, 1657–1665
54. Satin, J., Kyle, J. W., Chen, M., Bell, P., Cribbs, L. L., Fozzard, H. A., and
Rogart, R. B. (1992) Science 256, 1202–1205
55. Alzheimer, C., Schwindt, P. C., and Crill, W. E. (1993) J. Neurosci. 13,
660–673
56. Crill, W. E. (1996) Annu. Rev. Physiol. 58, 349–362
57. Numann, R., Catterall, W. A., and Scheuer, T. (1991) Science 254, 115–118
58. Taylor, C. P. (1993) Trends Neurosci. 16, 455–460
59. Taylor, C. P., and Narasimhan, L. S. (1997) Adv. Pharmacol. 39, 47–98
60. Cruz, L. J., Gray, W. R., Olivera, B. M., Zeikus, R. D., Kerr, L., Yoshikami, D.,
and Moczydlowski, E. (1985) J. Biol. Chem. 260, 9280–9288
Structure-Activity of -Conotoxin PIIIA 27255
 by on Septem
ber 7, 2006 
w
w
w
.jbc.org
D
ow
nloaded from
 
